



CSL SUPPLY AGREEMENT

28 September 2006: Clinical Cell Culture Ltd (C3, ASX: CCE) today announced that it had entered into a supply agreement with CSL Limited (ASX: CSL) for the supply of Trypsin, a key component of the Company's ReCell[®] tissue harvesting device.

ReCell[®] is a unique medical device that assists plastic, cosmetic, dermatology and burn surgeons in repairing a wide range of skin defects. ReCell[®] is intended for use in patients with injuries of up to 2% of the body surface or 320cm².

Under the terms of the agreement, C3 has committed to a minimum quantity of Trypsin from CSL over a 2 year period, resulting in a financial commitment of \$1 million.

CEO Bob Atwill said he was delighted that the supply of Trypsin had been secured with CSL, Australia's leading biopharmaceutical company.

"This agreement locks in the supply of enhanced formulations of Trypsin and the minimum purchase quantity reflects the anticipated increase in ReCell[®] sales in the next 2 years."

"We have worked with CSL for a number of years and we look forward to developing our relationship in the supply of this key component," said Mr Atwill.

President Asia Pacific CSL Bioplasma Tom Giarla said this agreement will continue our close working partnership and enable us to jointly develop the Trypsin product and technology platform.

- ENDS -

FOR FURTHER INFORMATION PLEASE CONTACT:

Andrew Cannon
Clinical Cell Culture
Tel: +44 (0) 1223 341 150
Email: investor@clinicalcellculture.com

Bob Atwill
Clinical Cell Culture
Tel: +61 (0) 448 778 880

FOR GENERAL INFORMATION PLEASE CONTACT:

John McGlue
Porter Novelli
Tel: +61 (0) 8 9386 1233
Mob: +61 (0) 417 926 915



ABOUT C3

Clinical Cell Culture (C3) is a publicly listed biomedical company that develops and distributes a number of tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissue-culture/collection technology, C3 is able to provide innovative treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.

PRODUCT PORTFOLIO

- C3 products use autologous cells obtained from the patients themselves to lower the risks for cross contamination and rejection. Further, the rapid harvest and culture time has the potential to significantly improve the rate of healing which can favourably impact the aesthetic and functional outcome for the patient and reduce overall costs. C3 continues research into the development of new tissue engineered products and medical devices for burn and wound healing.
- CellSpray[®] (www.cellspray.info) is a suspension containing cultured skin cells for use in the treatment of major burns and scars. Cells are harvested from a small skin sample (biopsy) and cultured in C3's laboratory over approximately 5 to 7 days. Traditional technologies take approximately 21 days to culture small sheets of skin.
- CellSpray[®] XP (www.cellspray.info) is a rapid version of CellSpray[®] that is available within 48-hours of a biopsy being taken. CellSpray[®] XP is generally applied to wounds that must be treated urgently
- ReCell[®] (www.recell.info) is a stand-alone, rapid cell harvesting device that enables surgeons to treat skin defects using the patient's own cells that are collected during surgery. The surgeon can prepare a small quantity of cells within 30 minutes on site rather than having to send a biopsy to the laboratory. ReCell[®] has been designed for use in a wide variety of plastic, reconstructive and cosmetic procedures.

Sales of all three products are now underway in several key markets, with distributors engaged to sell in additional markets as further approvals are confirmed.

C3's products have been used on more than 2,000 cases to date and have the potential to treat millions of patients worldwide.

PRODUCT DEVELOPMENT

C3 is currently working on a number of product development and enhancement projects. A reusable ReCell[®] device is being developed which will give C3 access to price sensitive markets. An enhanced spray head is also being developed which will enhance IP protection. New versions of Trypsin are being tested and reviewed to further improve the performance of ReCell[®] and provide C3 with additional IP protection.

ReCell[®] APPROVED MARKETS

Argentina, Australia, Austria, Belgium, Canada, Chile, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Luxembourg, Malaysia, New Zealand, Norway, Philippines, Poland, Portugal, Saudi Arabia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, The Netherlands, United Kingdom

CellSpray[®] APPROVED MARKETS

Austria, Denmark, Germany, The Netherlands, United Kingdom

CellSpray[®] XP APPROVED MARKETS

Austria, Denmark, Germany, Italy, Switzerland, The Netherlands, United Kingdom

ABOUT CSL

CSL Limited (ASX: CSL) is a global speciality biopharmaceutical company that develops, manufactures and markets products to treat and prevent serious human medical conditions.